Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke

PHASE3CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

November 10, 2019

Primary Completion Date

February 10, 2022

Study Completion Date

February 10, 2022

Conditions
Cerebral IschemiaCerebral InfarctionStroke, Acute
Interventions
DRUG

Normal Saline along with standard treatment

PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.

DRUG

PMZ-1620 (sovateltide) along with standard treatment

PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.

Trial Locations (11)

110029

All India Institute of Medical Sciences, New Delhi

110070

Indian Spinal Injury Centre, New Delhi

141001

Dayanand Medical College & Hospital, Ludhiana

141008

Department of Neurology, Christian Medical College and Hospital, Ludhiana

141421

Sidhu Hospital Pvt. Ltd., Ludhiana

160012

Post Graduate Institute of Medical Education and Research, Chandigarh

282002

Pushpanjali Hospital & Research Centre Pvt. Ltd, Agra

422005

Chopda Medicare & Research Centre, Nashik

440008

New Era Hospital & Research Institute, Nagpur

444606

Radiant Superspeciality Hospital, Amravati

522001

Lalitha Superspecialities Hospital, Guntur

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pharmazz, Inc.

INDUSTRY

NCT04047563 - Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter